We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 2,252

Intellectual property issues of biomedical outsourcing in the PRC
  • King & Wood Mallesons
  • China
  • September 12 2012

As a result of the development of the biomedical industry and the Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) business models, China has become one of the most important outsourcing destination countries, acquiring considerable market share of the global outsourcing market

A call for more collaboration in industrial biotech
  • Kaye Scholer LLP
  • USA
  • August 28 2012

The growing shortage and rising price of fossil energy has increased interest in finding economically attractive replacements that draw on biotechnology

Conduct of fundamental research can still implicate U.S. export control laws
  • Baker & Hostetler LLP
  • USA
  • August 30 2012

Most research institutions are aware that an exemption for "fundamental research" exists under U.S. export control laws

Bring-your-own device policies present special challenges for the health care sector
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • October 2 2012

The use of employee-owned devices in the business setting often referred to as “bring-your-own-device” or “BYOD” presents data security challenges for all businesses

UK Office of Fair Trading report on the Pharmaceutical Price Regulation Scheme
  • Bird & Bird
  • United Kingdom
  • March 9 2007

On 20 February 2007, the Office of Fair Trading (“OFT”) published a 120 page report on the regulation of the price of branded pharmaceutical products under the voluntary scheme that is periodically re-negotiated between the industry and the Department of Health, the Pharmaceutical Price Regulation Scheme (“PPRS”

Supreme Court in Medimmune opens the courthouse doors to licensees who challenge the scope or validity of licensed patents
  • Fenwick & West LLP
  • USA
  • April 2 2007

The Supreme Court has ruled that patent licensees do not need to breach their license agreements before seeking a declaratory judgment in federal court that the underlying patent is invalid, unenforceable, or not infringed

Pharmaceutical patent litigation settlements continue to be a hot topic
  • Drinker Biddle & Reath LLP
  • USA
  • April 17 2007

Despite some recent setbacks, the Federal Trade Commission (“FTC”) is still focused on so-called “reverse payments” from innovator pharmaceutical companies to generic drug manufacturers made in connection with the settlement of patent litigation

Invalidity ruling does not necessarily entitle licensee to stop royalty payments
  • Locke Lord LLP
  • USA
  • April 17 2007

An invalidity ruling in a separate lawsuit does not relieve a patent licensee from owing royalties under the U.S. Supreme Court’s Lear Inc. v. Adkins doctrine, the Federal Circuit has held

Are supplementary protection certificates keeping pace with drug development?
  • McDermott Will & Emery
  • United Kingdom, European Union
  • April 10 2007

The pharmaceutical and biotechnology industries are heavily dependent on patents as a means of securing future revenues

Why life science patents are a breed apart
  • McDermott Will & Emery
  • European Union
  • April 10 2007

Patents are creatures of statute. Once an applicant has disclosed an invention, and subject to the application meeting certain statutory standards as to form and content, the European Patent Office grants a 20-year “monopoly”